ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2024
Association Between Percent Body Fat Reduction and Changes of the Metabolic Score for Insulin Resistance in Overweight/Obese People with Metabolic Dysfunction-Associated Steatotic Liver Disease.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Adipocyte Size, Overweight, and Insulin Resistance in Type 2 Diabetes Mellitus and the Impact of Weight Loss: A Systematic Review.Nutrients · 2026Pooled it
- The effects of high-intensity interval training versus continuous moderate-intensity exercise on body composition among older adults with HIV.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Trial
- Changes in Insulin Resistance with Different Weight Loss Methods in Patients with Type Two Diabetes Mellitus and Hypertension: A Comparative Clinical Trial.Journal of clinical medicine · 2026Article
- Machine learning-based model for predicting metabolic dysfunction-associated steatotic liver disease using non-invasive parameters in young adults.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study investigated the relationship between the difference in percent body fat (∆PBF) decrease and the change in the metabolic score for insulin resistance (METS-IR) in Chinese overweight/obese people with combined metabolic dysfunction-associated steatotic liver disease (MASLD) after weight loss. Patients and Methods: A total of 357 overweight/obese MASLD patients were included using a retrospective study method. The subjects were divided into two groups (< 5% and ≥ 5%) based on the ∆PBF. The changes in METS-IR (∆METS-IR) and metabolic indices before and after fat loss were compared between the two groups. Spearman correlation analysis was employed to investigate the correlation between METS-IR changes and the decrease in PBF. A linear regression model was fitted using a restricted cubic spline (RCS) curve to investigate the dynamic relationship between ∆METS-IR and ∆PBF. Results: Following the fat reduction, both groups' body measurements and liver fat content exhibited a notable reduction, accompanied by a decline in METS-IR. In particular, the decrease in METS-IR was more pronounced in the group with a ≥5% decrease in PBF. Significant correlations were observed between ∆PBF and various insulin resistance indices. The correlation between ΔPBF and ∆METS-IR was noteworthy ( Conclusion: The reduction of PBF was closely associated with changes in METS-IR, indicating that fat loss is an effective method for improving insulin resistance in overweight/obese MASLD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.